Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
| ▸ | GABRE | P78334 | 1/20 | 0.31 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.31 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.31 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.31 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11308300 | 0.94 | ALDH1A1 (0.43) | ALDH1A1TLR8TLR7NPSR1 | |
| SCHEMBL6174246 | 0.78 | ALDH1A1 (0.32) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11585839 | 0.76 | ALDH1A1 (0.42) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11633106 | 0.73 | MEN1 (0.36) | ALDH1A1 | |
| SCHEMBL13801060 | 0.73 | ALDH1A1 (0.45) | ALDH1A1TLR8TLR7TSHRNPSR1 | |
| SCHEMBL28331464 | 0.72 | ALDH1A1 (0.50) | ALDH1A1TLR8TLR7 | |
| SCHEMBL27417193 | 0.72 | AGER (0.36) | — | |
| SCHEMBL9643993 | 0.72 | GABRP (0.43) | ALDH1A1TLR8TLR7TSHRGABRP | |
| SCHEMBL21785277 | 0.69 | GRM5 (0.36) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL5138095 | 0.69 | HRH3 (0.41) | ALDH1A1TSHRGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104004509-A | Organo-boron group-containing phosphorescent organic electroluminescent material and preparation method thereof | UNIV XI AN JIAOTONG | 2014-08-27 | — | — | CN | disclosed |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7122546-B2 | Imidazol-1-ylmethyl pyridazine derivatives | NEUROGEN CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1647545-A1 | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1005493-B1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| EP-1549636-A1 | IMIDAZOL-1-YLMETHYL PYRIDAZINE DERIVATIVES | Neurogen Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2004-09-23 | — | — | US | disclosed |
| EP-1173210-B1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | WYETH CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6759408-B2 | CYCLIC COMBINATION THERAPIES AND REGIMENS UTILIZING SUBSTITUTED INDOLINE DERIVATIVE COMPOUNDS WHICH ARE ANTAGONISTS OF THE PROGESTERONE RECEPTOR | WYETH | 2004-07-06 | — | — | US | disclosed |
| US-6566358-B2 | 1,4-dihydro-benzo(d)oxazin-2-one derivatives useful for treating hormone-dependent neoplastic disease is selected from uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy, carcinomas, and adenocarcinoma | WYETH | 2003-05-20 | — | — | US | disclosed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6489364-B2 | FROM L-MANNONIC-GAMMA-LACTONE INTERMEDIATES; FOR PROPHYLAXIS OF HIV/AIDS HIV | MEDIVIR AB (SE) | 2002-12-03 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| US-20010044547-A1 | Antiviral protease inhibitors | MEDIVIR AB | 2001-11-22 | — | — | US | disclosed |
| US-6291687-B1 | USED ASPARTYL PROTEASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) | MEDIVIR AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1005493-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998045330-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | ALDH1A1 1981/4885TLR8 2051/4885TLR7 2446/4885 |
| US-20010044547-A1 | Antiviral protease inhibitors | PEPD, PREP, CTSL | ALDH1A1 1578/4885TLR8 3383/4885TLR7 3352/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | ALDH1A1 1401/4885TLR8 3887/4885TLR7 3038/4885 |
| US-20040186101-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | PGR, NR3C2, NR5A1 | ALDH1A1 2671/4885TLR8 3310/4885TLR7 2004/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | ALDH1A1 3329/4885TLR8 2837/4885TLR7 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.